Furthermore, a phase I study with the use of RO6874281, an immunocytokine containing of an interleukin-2 variant (IL-2v) fused with an anti-FAP antibody targeted to tumour-associated fibroblasts via binding to FAP, showed a significant increase in the activity of T and NK cells and caused a durable response in one patient with HNSC [504]. This evidence concerns the gene IL2 and neoplasm.